HORIZON EUROPE
European
Specific Challenge:Diabetes contributes to the development of heart failure (HF) indirectly by promoting the progression of coronary artery disease and directly through the development of cardiomyopathy. Thus, diabetic patients have a 2.5-fold greater risk for HF as compared to those without diabetes. Epidemiological studies have reported a 4-fold higher prevalence of diabetes mellitus in HF patients (20%) compared to age-matched populations without HF (5%) which rises up to 40% in hospitalised HF patients. Over the last decades it became clear that there is a relationship between diabetes and HF, although not all patients with diabetes develop cardiomyopathy or evolve toward HF.
The overall objective of this topic is to determine whether diabetic cardiomyopathy is unique and distinct from the other forms of heart failure such as HFpEF (heart failure with preserved ejection fraction) or HCM (hypertrophic cardiomyopathy) by performing unbiased statistical clustering analysis from a dense phenotyping of these patient populations.
Furthermore, a better comprehension of the underlying mechanisms and clinical manifestations of diabetic cardiomyopathy will also...
see more
Specific Challenge:Diabetes contributes to the development of heart failure (HF) indirectly by promoting the progression of coronary artery disease and directly through the development of cardiomyopathy. Thus, diabetic patients have a 2.5-fold greater risk for HF as compared to those without diabetes. Epidemiological studies have reported a 4-fold higher prevalence of diabetes mellitus in HF patients (20%) compared to age-matched populations without HF (5%) which rises up to 40% in hospitalised HF patients. Over the last decades it became clear that there is a relationship between diabetes and HF, although not all patients with diabetes develop cardiomyopathy or evolve toward HF.
The overall objective of this topic is to determine whether diabetic cardiomyopathy is unique and distinct from the other forms of heart failure such as HFpEF (heart failure with preserved ejection fraction) or HCM (hypertrophic cardiomyopathy) by performing unbiased statistical clustering analysis from a dense phenotyping of these patient populations.
Furthermore, a better comprehension of the underlying mechanisms and clinical manifestations of diabetic cardiomyopathy will also allow the development of more translatable and predictable preclinical models to support target and drug discovery.
Scope:The overall goal of the proposed topic is to assess the uniqueness of diabetic cardiomyopathy and to unveil the underlying mechanisms of cardiomyopathy in diabetic patients and the impact on cardio-vascular mortality in this population, which may finally allow the clustering of patients into an independent cohort. In consequence, this improved understanding of the clinical manifestations and diagnosis of diabetic cardiomyopathy as well as the linkage between the onset and disease progression with a specific signature will enable patient stratification at an early stage of the disease by clustering of patients into an independent cohort.
Expected Impact:In terms of research and development (R&D), clinical, regulatory, healthcare practice and patient management:
proposals are expected to define and assess key phenotypes that characterise diabetic cardiomyopathy and could serve to establish patient diagnosis and ultimately prognosis;the stratification of patients into the diabetic cardiomyopathy cluster based on pheno-mapping, supported by biomarkers specific for this group will be transformative for the clinical management of these patients;furthermore, novel pre-clinical models with improved knowledge on the translatability to humans will profoundly enable drug development for the treatment of diabetic cardiomyopathy beyond blood glucose control. Overall, a better comprehension of the mechanisms and clinical manifestations of diabetic cardiomyopathy will allow the development of more translatable and predictable preclinical models supporting target and drug discovery in academia and industry. The molecular taxonomy of diabetic cardiomyopathy to be developed will enable innovative and individualised treatment options for patients.
In terms of strengthening the competitiveness and industrial leadership in Europe the applicants could also include the relevant expertise from the small- and medium-sized enterprises (SMEs).Their involvement might offer a complementary perspective to industry and the academia, and help deliver the long-term impact of the project.
see less
Consortium characteristics
:
The aid is European, you can apply to this line any company that is part of the European Community.
characteristics of the Proyecto
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Characteristics of financing
The IMI2 13th Call for proposals topic text as well as the Call Conditions are available here.
The budget breakdown for this Call is given at the end of the Call topics text, in the Call Condtions section, as well as the following information:
1. Eligible countries: described in article 10(2) of the Rules for participation in Horizon 2020 and in article 1 of the Commission Delegated Regulation related to IMI JU.
2. Eligibility and admissibility conditions: described in the IMI2 Manual for evaluation, submission and grant award. See also the Commission Delegated Regulation related to IMI JU.
Proposal page limits and layout: Please refer to Part B of the proposal template in the submission tool below.
3. Evaluation:
Submission and evaluation process, including evaluation criteria and procedure, scoring and threshold are described in the IMI2 Manual for submission, evaluation and grant award. See also the proposal templates for your specific action in section 5, below.
4. Indicative time for evaluation and grant agreement:
Notification of outcomes of stage 1 evaluations: maximum 5 months from deadline for submitting proposals.
Notification of outcomes of stage 2 evaluations: maximum 5 months from deadline for submitting full p... Please read carefully all provisions below before the preparation of your application.
The IMI2 13th Call for proposals topic text as well as the Call Conditions are available here.
The budget breakdown for this Call is given at the end of the Call topics text, in the Call Condtions section, as well as the following information:
1. Eligible countries: described in article 10(2) of the Rules for participation in Horizon 2020 and in article 1 of the Commission Delegated Regulation related to IMI JU.
2. Eligibility and admissibility conditions: described in the IMI2 Manual for evaluation, submission and grant award. See also the Commission Delegated Regulation related to IMI JU.
Proposal page limits and layout: Please refer to Part B of the proposal template in the submission tool below.
3. Evaluation:
Submission and evaluation process, including evaluation criteria and procedure, scoring and threshold are described in the IMI2 Manual for submission, evaluation and grant award. See also the proposal templates for your specific action in section 5, below.
4. Indicative time for evaluation and grant agreement:
Notification of outcomes of stage 1 evaluations: maximum 5 months from deadline for submitting proposals.
Notification of outcomes of stage 2 evaluations: maximum 5 months from deadline for submitting full proposals.
Signature of grant agreements: maximum 3 months from the date of informing successful applicants.
5. Proposal templates, evaluation forms and model grant agreements (MGA), clinical trials template:
IMI2 Research and Innovation Action (IMI2-RIA) and Innovation Action (IMI2-IA):
Proposal templates are available after entering the submission tool.
Standard evaluation form RIA
IMI2 Model Grant Agreement:
Members of consortium are required to conclude a consortium agreement prior to the signature of the grant agreement.
Clinical trial template:
The Clinical Trial template is compulsory at stage 2 only !
IMI2 Coordination and Support Action (IMI2-CSA):
Proposal templates are available after entering the submission tool.
Standard evaluation form CSA
IMI2 Model Grant Agreement:
Members of consortium are required to conclude a consortium agreement prior to the signature of the grant agreement.
Clinical trial template:
The Clinical Trial template is compulsory at stage 2 only !
6. Open access must be granted to all scientific publications resulting from Horizon 2020 actions.
Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.
Open access to research data
The Open Research Data Pilot has been extended to cover all Horizon 2020 topics for which the submission is opened on 26 July 2016 or later. Projects funded under this topic will therefore by default provide open access to the research data they generate, except if they decide to opt-out under the conditions described in Annex L of the H2020 main Work Programme. Projects can opt-out at any stage, that is both before and after the grant signature.
Note that the evaluation phase proposals will not be evaluated more favourably because they plan to open or share their data, and will not be penalised for opting out.
Open research data sharing applies to the data needed to validate the results presented in scientific publications. Additionally, projects can choose to make other data available open access and need to describe their approach in a Data Management Plan.
Projects need to create a Data Management Plan (DMP), except if they opt-out of making their research data open access. A first version of the DMP must be provided as an early deliverable within six months of the project and should be updated during the project as appropriate. The Commission already provides guidance documents, including a template for DMPs. See the Online Manual.
Eligibility of costs: costs related to data management and data sharing are eligible for reimbursement during the project duration.
The legal requirements for projects participating in this pilot are in the article 29.3 of the Model Grant Agreement.
7. Additional documents:
Summary of the most relevant provisions for participating in IMI2 actions
IMI2 - 2nd Amendment to the Annual Work Plan 2017
IMI2 Regulators Guidance tool for researchers
IMI JU derogation to H2020 Rules for Participation
Horizon 2020 Rules for Participation
Horizon 2020 Regulation of Establishment
Horizon 2020 Specific Programme
Members of consortium are required to conclude a consortium agreement prior to the signature of the grant agreement.
Additional information about the call
other advantages
